Given the evidence from other research laboratories and our own indicating that a reduction in mTORC2 activity promotes CD8+ memory T cell differentiation and response46 as well as NK cell cytolytic function, the exploration of inhibitors that selectively repress mTORC2 activity would be of immense research benefit, especially considering that mTORC2 abnormalities are associated with many human cancers, including prostate, breast, and non–small-cell lung cancers, glioblastoma, and T cell acute lymphoblastic leukemia8, 48. The gene discussed is CD8A; the disease is lung cancer.